Even with approval, the FDA has instructed Eli Lilly to study the heart, liver, and other potential risks associated with this new pill
Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, Su Y, Chan D, Tillman EJ, Moulton A, de Temple B, Zari A, Shringarpure R, Rolph T, Cheng A, Yale K
(Refer to Table 1 for details of clinical trials evaluating GLP-1 and insulin)
All can be used by adults, but some are also approved for children
The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead
What mechanisms of action allow liraglutide to manage Type 2 diabetes and support weight loss, and how do these mechanisms compare to other treatments like metformin or insulin glargine